Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Paul Kenny
Icahn School of Medicine at Mount Sinai, Department: Neurosciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eolas Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Paul Kenny (the Principal Investigator on this study, Ward-Coleman Professor and Chair of the Dorothy H. and Lewis Rosenstiel Department of Pharmacology and Systems Therapeutics) is a co-founder and equity holder in Eolas Therapeutics, a privately held company that is working to develop compounds to treat nicotine and cocaine addiction.
Defining the Role of D1 and D2 Medium Spiny Neurons in Relapse to Cocaine Seeking
Project Narrative Drug abuse and addiction are syndromes that severely damage the lives of affected patients and their families, and constitute a major public health concern in the United States. Cocaine addiction is characterized by cycles of drug binges followed by abstinence and subsequent relapse; thus, pharmacological interventions that reduce cocaine craving and drug seeking during the abstinence period are ideal for preventing relapse. By studying cocaine self-administration, a paradigm that models chronic cocaine abuse in humans, we will be able to determine the neurochemical consequences of cocaine abuse and withdrawal in an attempt to develop novel pharmacotherapies to combat cocaine addiction and improve treatment outcomes in cocaine addicts.
Filed on August 01, 2016.
Tell us what you know about Paul Kenny's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Paul Kenny”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Paul Kenny | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Eolas Therapeutics | $40,000 - $59,999 |
| Paul Kenny | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Eolas Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.